TNFRSF17 and Miyoshi myopathy: Of concern were WM on-therapy (G1, BTKi or rituximab) and MM (G3, anti-CD38, anti-BCMA) cohorts with a substantial number of patients (50–90%) who developed very low Spike-RBD antibodies.